I have already developed a new unique treatment for lung emphysema in COPD patients and obtained very promising in vitro results. In line with these, I expect to observe that the Lung-bioECM promotes the regeneration of the damaged lung tissue in a relevant animal model of emphysema. This will motivate the patenting of this innovative therapy prior to further pre-clinical and clinical evaluations for its use in COPD patients. Ultimately, this approach may be extrapolated to other diseases.
